Results 1 to 19 of 19
Page 1 of 1
TypeTitleAuthor(s)YearViews
eGFR improvement in chronic hepatitis b patients with telbivudine treatment is independent of antiviral activityGane, EJ; Liaw, YF; Wang, Y; Lai, CL; Rasenack, J; Zeuzem, S; Chan, HLY; Ren, H; Dong, Y; Uddin, A; Jung, ME; Bosset, S; Trylesinski, A201330
 
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BChang, TT; Liaw, YF; Wu, SS; Schiff, E; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, Z; Chi, YC; Zhang, H; Hindes, R; Iloeje, U; Beebe, S; Kreter, B2010130
 
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinomaOmata, M; Lesmana, LA; Tateishi, R; Chen, PJ; Lin, SM; Yoshida, H; Kudo, M; Lee, JM; Choi, BI; Poon, RTP; Shiina, S; Cheng, AL; Jia, JD; Obi, S; Han, KH; Jafri, W; Chow, P; Lim, SG; Chawla, YK; Budihusodo, U; Gani, RA; Lesmana, CR; Putranto, TA; Liaw, YF; Sarin, SK2010130
 
Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patientsHsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P2009322
 
Errata: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateLiaw, YF; Leung, N; Kao, JH; Piratvisuth, T; Gane, E; Han, KH; Guan, R; Lau, GKK; Locarnini, S; The Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver2008129
 
Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901.Liaw, YF; Chang, TT; Wu, SS; Schiff, ER; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, ZD; Zhang, H; Hindes, R; Hoeje, U; Beebe, S; Kreter, B2008202
 
Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901Sherman, M; Rizzetto, M; Lai, CL; Liaw, YF; Gadano, A; Jacobson, IM; Schiff, ER; Yang, J; Colonno, R; Kreter, B; Hindes, R2007106
 
Telbivudine versus lamivudine in patients with chronic hepatitis BLai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA2007257
 
Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis BNaoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N200699
 
Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 yearGane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006120
 
Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patientsZeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N2006126
 
Entecavir (ETV) vs. Adefovir (ADV): HBV DNA reduction of viral load in chronically infected HBeAg(+) nucleoside naive adults in a 12-weekSherman, M; Hann, HW; Jeffers, L; Min, A; Leung, N; Peng, CY; Liaw, YF; Sollano, J; Lesmana, L; Yuen, RMF; Zhu, J; Mencarini, K; Colonno, R; Cross, A; Wilber, R; Lopez-Talavera, JC2006122
 
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trialLai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005157
 
Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study)Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, .2005134
 
High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis BLin, CL; Tsai, SL; Lee, TH; Chien, RN; Liao, SK; Liaw, YF2005195
 
Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis [4] (multiple letters)Chen, YC; Liaw, YF; Yuen, MF; Wong, DKH; Lai, CL200447
 
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis BPerrillo, RP; Lai, CL; Liaw, YF; Dienstag, JL; Schiff, ER; Schalm, SW; Heathcote, EJenny; Brown, NA; Atkins, M; Woessner, M; Gardner, SD2002111
 
Effects of extended lamivudine therapy in asian patients with chronic hepatitis BLiaw, YF; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Chien, RN; Dent, J; Roman, L; Edmundson, S; Lai, CL200068
 
12 months lamivudine (100mg od) therapy improves liver histology: results of a placebo controlled multicentre study in AsiaLai, CL; Liaw, YF; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Wu, PC; Dent, JC; Gray, DF1997208
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download